| ADHD Directory |
| ADHD Printables |
| ADHD Webinars |
| ADHD Guides |
| Expert Answers |
| ADHD News |
| Tools and Checklists |
| ADHD Topics A-Z |
| Book Reviews |
 |
| ADHD Groups |
| ADHD Discussions |
| ADHD Blogs |
| Share Your Story |
| E-Newsletters |
| ADHD Events |
| ADHD Videos |
|
| Subscribe |
| Give a Gift |
| Current Issue |
| Digital |
| Archives |
| Buy Back Issues |
| Buy Booklets |
| Customer Service |
| Contact Us |
| Advertise |
Drug Maker Shire Expands to EuropeThe maker of Vyvanse has a new presence in European markets. Monday February 23rd - 11:11am Filed Under:
ADHD Medication and Children,
ADHD Stimulant Medications
ADDitude Magazine
Pharmaceutical company Shire, maker of Vyvanse, has acquired rights to Equasym, a European medication used for the treatment of attention deficit hyperactivity disorder (ADD ADHD). Shire will continue to market Equasym within Europe, but it is not currently approved within the U.S. and Canada. Shire is also testing Vyvanse (now in Phase 3 trials) for approval in Europe. Says Michael Cola, president of Shire’s Specialty Pharmaceuticals business: “Our expertise and portfolio of ADHD products will provide a strong foundation from which we can offer innovative treatments for adults and children with ADHD.” Read more from Shire.
 |
|
Print
